Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
EBS Emergent BioSolutions	$6.40 +34.9%	$5.15	$4.02 ▼ $15.10	$347.49M	2.09	1.90 million shs	4.72 million shs
RGLS Regulus Therapeutics	$7.85	$2.63	$0.83 ▼ $8.20	$520.01M	0.49	870,934 shs	696,175 shs
VNDA Vanda Pharmaceuticals	$4.22 -3.8%	$4.54	$3.85 ▼ $6.75	$248.41M	0.69	731,189 shs	838,237 shs
VSTM Verastem	$6.94 +3.7%	$6.33	$2.10 ▼ $13.52	$357.34M	0.85	1.05 million shs	3.52 million shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
EBS Emergent BioSolutions	+35.06%	+30.30%	+49.94%	-36.05%	+45.01%
RGLS Regulus Therapeutics	0.00%	0.00%	+390.63%	+559.66%	+245.81%
VNDA Vanda Pharmaceuticals	-3.77%	-5.07%	+1.81%	-12.19%	-21.36%
VSTM Verastem	+3.80%	-6.59%	+49.57%	+19.86%	-39.12%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
EBS Emergent BioSolutions	4.2346 of 5 stars	3.5	1.0	4.6	2.8	2.5	1.3
RGLS Regulus Therapeutics	1.593 of 5 stars	2.1	5.0	0.0	2.5	1.7	0.0
VNDA Vanda Pharmaceuticals	4.1622 of 5 stars	3.5	1.0	4.2	2.0	3.3	1.3
VSTM Verastem	3.141 of 5 stars	4.5	1.0	0.0	3.0	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
EBS Emergent BioSolutions	3.00	Buy	$14.33	124.13% Upside
RGLS Regulus Therapeutics	2.29	Hold	$8.50	8.28% Upside
VNDA Vanda Pharmaceuticals	3.00	Buy	$16.50	291.46% Upside
VSTM Verastem	3.00	Buy	$13.89	100.13% Upside

Current Analyst Ratings Breakdown

Latest RGLS, VSTM, EBS, and VNDA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/7/2025	VNDA Vanda Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00 ➝ $20.00
5/1/2025	RGLS Regulus Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Equal Weight	$9.00
4/30/2025	RGLS Regulus Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
4/30/2025	RGLS Regulus Therapeutics	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
4/30/2025	RGLS Regulus Therapeutics	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Market Perform	$7.00
4/30/2025	RGLS Regulus Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold	$28.00 ➝ $11.00
4/30/2025	RGLS Regulus Therapeutics	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold	$8.00 ➝ $7.00
4/10/2025	VSTM Verastem	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$15.00
4/9/2025	VSTM Verastem	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$9.00 ➝ $8.00
4/1/2025	EBS Emergent BioSolutions	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$15.00 ➝ $15.00
4/1/2025	VNDA Vanda Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00 ➝ $20.00

(Data available from 5/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
EBS Emergent BioSolutions	$1.01B	0.34	$0.72 per share	8.92	$12.51 per share	0.51
RGLS Regulus Therapeutics	N/A	N/A	N/A	N/A	$1.05 per share	N/A
VNDA Vanda Pharmaceuticals	$198.77M	1.25	N/A	N/A	$9.23 per share	0.46
VSTM Verastem	$10M	35.73	N/A	N/A	$2.27 per share	3.06

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
EBS Emergent BioSolutions	-$760.50M	-$3.73	N/A	3.09	N/A	-18.55%	-9.91%	-3.31%	N/A
RGLS Regulus Therapeutics	-$30.04M	-$0.87	N/A	N/A	N/A	N/A	-53.07%	-48.58%	N/A
VNDA Vanda Pharmaceuticals	-$18.90M	-$0.32	N/A	N/A	N/A	-9.51%	-3.49%	-2.90%	N/A
VSTM Verastem	-$87.37M	-$3.50	N/A	N/A	N/A	N/A	-332.73%	-73.97%	N/A

Latest RGLS, VSTM, EBS, and VNDA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/8/2025	Q1 2025	RGLS Regulus Therapeutics	-$0.33	-$0.15	+$0.18	-$0.15	N/A	N/A
5/7/2025	Q1 2025	EBS Emergent BioSolutions	$0.49	$0.71	+$0.22	$1.19	$218.50 million	$222.20 million
5/7/2025	Q1 2025	VNDA Vanda Pharmaceuticals	-$0.55	-$0.50	+$0.05	-$0.50	$45.13 million	$50.04 million
3/20/2025	Q4 2024	RGLS Regulus Therapeutics	-$0.20	-$0.20	N/A	-$0.20	N/A	N/A
3/20/2025	Q4 2024	VSTM Verastem	-$0.76	-$1.33	-$0.57	-$1.33	$0.15 million	N/A
3/3/2025	Q4 2024	EBS Emergent BioSolutions	-$0.35	$0.05	+$0.40	-$0.58	$254.67 million	$194.70 million
2/13/2025	Q4 2024	VNDA Vanda Pharmaceuticals	-$0.14	-$0.08	+$0.06	-$0.08	$51.00 million	$53.19 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
EBS Emergent BioSolutions	N/A	N/A	N/A	N/A	N/A
RGLS Regulus Therapeutics	N/A	N/A	N/A	N/A	N/A
VNDA Vanda Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
VSTM Verastem	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
EBS Emergent BioSolutions	1.30	2.88	1.47
RGLS Regulus Therapeutics	N/A	14.15	14.14
VNDA Vanda Pharmaceuticals	N/A	4.39	4.37
VSTM Verastem	2.77	3.23	3.23

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
EBS Emergent BioSolutions	78.40%
RGLS Regulus Therapeutics	92.38%
VNDA Vanda Pharmaceuticals	88.14%
VSTM Verastem	88.37%

Insider Ownership

Company	Insider Ownership
EBS Emergent BioSolutions	1.20%
RGLS Regulus Therapeutics	4.35%
VNDA Vanda Pharmaceuticals	8.90%
VSTM Verastem	2.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
EBS Emergent BioSolutions	2,420	54.34 million	53.53 million	Optionable
RGLS Regulus Therapeutics	30	66.24 million	62.65 million	Optionable
VNDA Vanda Pharmaceuticals	290	58.93 million	53.13 million	Optionable
VSTM Verastem	50	51.49 million	43.53 million	Optionable

RGLS, VSTM, EBS, and VNDA Headlines

Recent News About These Companies

Verastem Ovarian-Cancer Drug Combination Gets FDA Approval -- Update

May 8 at 9:03 PM | marketwatch.com

FDA Approves Verastem's Avmapki, Fakzynja Combo for KRAS-Mutant Ovarian Cancer Patients

May 8 at 9:03 PM | precisionmedicineonline.com

Verastem’s Combination Therapy For Ovarian Cancer Gets FDA Approval: Retail’s Pleased

May 8 at 9:03 PM | msn.com

FDA Grants Accelerated Approval To Verastem's Combination Drug For Ovarian Cancer

May 8 at 3:18 PM | benzinga.com

Verastem’s Breakthrough FDA Approval and Market Potential for KRAS Mutant LGSOC Therapy

May 8 at 2:18 PM | tipranks.com

FDA Approves the AVMAPKI™ FAKZYNJA™ Combination Therapy as the First-Ever Treatment for Adult Patients with KRAS-mutated Recurrent Low-Grade Serous Ovarian Cancer

May 8 at 1:17 PM | businesswire.com

U.S. FDA approves Verastem's cancer therapy

May 8 at 12:23 PM | reuters.com

Susquehanna Fundamental Investments LLC Buys New Shares in Verastem, Inc. (NASDAQ:VSTM)

May 7 at 4:19 AM | marketbeat.com

Verastem, Inc. (NASDAQ:VSTM) Holdings Boosted by BVF Inc. IL

May 6 at 7:31 AM | marketbeat.com

B. Riley Has Pessimistic Outlook of Verastem Q2 Earnings

May 3, 2025 | marketbeat.com

Verastem (VSTM) to Release Earnings on Thursday

May 3, 2025 | marketbeat.com

B. Riley Has Optimistic Outlook of Verastem FY2029 Earnings

May 2, 2025 | marketbeat.com

Verastem Oncology to Present at Upcoming Investor Conferences

May 2, 2025 | finance.yahoo.com

B. Riley Issues Negative Forecast for Verastem Earnings

May 2, 2025 | americanbankingnews.com

Verastem, Inc. (NASDAQ:VSTM) Shares Bought by Geode Capital Management LLC

April 28, 2025 | marketbeat.com

Marshall Wace LLP Invests $4.10 Million in Verastem, Inc. (NASDAQ:VSTM)

April 27, 2025 | marketbeat.com

Verastem Oncology Announces $75 million Private Placement | VSTM Stock News

April 25, 2025 | gurufocus.com

Verastem Oncology Announces $75 million Private Placement

April 25, 2025 | gurufocus.com

Verastem Oncology Announces $75 million Private Placement

April 25, 2025 | finance.yahoo.com

Verastem Oncology rises on $75M private placement

April 25, 2025 | seekingalpha.com

Verastem announces U.S. IND clearance of VS-7375

April 25, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

RGLS, VSTM, EBS, and VNDA Company Descriptions

Emergent BioSolutions NYSE:EBS

$6.40 +1.66 (+34.92%)

Closing price 05/8/2025 03:59 PM Eastern

Extended Trading

$6.47 +0.08 (+1.17%)

As of 05:07 AM Eastern

Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It also provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; BAT for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Reactive Skin Decontamination Lotion Kit to remove or neutralize chemical warfare agents from the skin; Trobigard, a atropine sulfate obidoxime chloride auto-injector. In addition, the company is developing CGRD-001 for the treatment of poisoning by organophosphorus nerve agents or organophosphorus compounds; EBS-LASV to prevent Lassa fever; EBS-MARV to prevent Marburg virus disease; EBS-SUDV to prevent Sudan virus disease; Pan-Ebola mAbs for the treatment of ebola virus; SIAN Antidote for initial treatment of certain or suspected acute cyanide poisoning; UniFlu for immunity against influenza A and B viruses; and WEVEE-VLP for equine encephalitis virus infections. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.

Regulus Therapeutics NASDAQ:RGLS

$7.85 0.00 (0.00%)

Closing price 05/8/2025 04:00 PM Eastern

Extended Trading

$7.84 0.00 (-0.06%)

As of 04:03 AM Eastern

Regulus Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.

Vanda Pharmaceuticals NASDAQ:VNDA

$4.22 -0.17 (-3.77%)

Closing price 05/8/2025 03:59 PM Eastern

Extended Trading

$4.14 -0.07 (-1.66%)

As of 04:59 AM Eastern

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its pipeline products include HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, delayed sleep phase disorder, sleep disturbances in autism spectrum disorder, and pediatric Non-24; Fanapt (iloperidone) for the treatment of bipolar I disorder and Parkinson's disease psychosis, as well as a long acting injectable (LAI) formulation to treat schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist to treat gastroparesis, motion sickness, atopic dermatitis, and COVID-19 pneumonia. The company's pipeline products also include VTR-297, a small molecule histone deacetylase inhibitor to treat hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist to treat performance anxiety and psychiatric disorders; VHX-896, an active metabolite of iloperidone; and antisense oligonucleotide molecules. In addition, it offers a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors that include VSJ-110 for the treatment of dry eye and ocular inflammation; and VPO-227 for the treatment of secretory diarrhea disorders comprising cholera. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.

Verastem NASDAQ:VSTM

$6.94 +0.25 (+3.74%)

Closing price 05/8/2025 04:00 PM Eastern

Extended Trading

$7.26 +0.32 (+4.54%)

As of 06:11 AM Eastern

Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The company is involved in clinical studies, including RAMP 301, a randomized global confirmatory trial to evaluate the combination of Avutometinib and Defactinib for the treatment of patients with recurrent low-grade serous ovarian cancer; RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of Avutometinib and in combination with Defactinib; and FRAME, an investigation of Avutometinib and Defactinib in patients with KRAS mutant cancers and subsequent analyses; and RAMP 204 and 205. It has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing Avutometinib; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic, and prophylactic uses in humans. In addition, it has a clinical collaboration agreement with Amgen, Inc. to evaluate the combination of Avutometinib with Amgen's KRAS-G12C inhibitor LUMAKRAS which in Phase 1/2 trial entitled RAMP 203; and a discovery and development collaboration with GenFleet Therapeutics to advance new programs targeting RAS pathway-driven cancers. Verastem, Inc. was incorporated in 2010 and is headquartered in Needham, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time